Knock-Out Technologies to test Proxorin
Knock-Out Technologies Ltd., a wholly-owned subsidiary of eFoodSafety.com, is set to begin clinical testing of Proxorin™ for use as a natural antibiotic/anti-microbial in the treatment of common bacterial pathogens. The drug is based on the company’s CitroxinTM formula. Due to its natural composition, Proxorin may be used in a much larger range of health conditions than that addressed by antibiotics.
- HepaLife bioartificial liver device surpasses expectations
- NCode™ Human and Mouse non-coding RNA microarray launched
- FDA 510(k) clearance to Baxter’s Anti-Pathogen technology
- ThromboVision commences clinical trials for T-Guide(R)
